3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with Lung Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CH; Chen, MC; Liu, YN; Pan, SL; Teng, CM; Wang, HP | 1 |
| Bartolucci, AA; Oldham, R; Presant, CA; Ungaro, P | 1 |
2 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and Lung Neoplasms
| Article | Year |
|---|---|
TW01001, a novel piperazinedione compound, induces mitotic arrest and autophagy in non-small cell lung cancer A549 cells.
Topics: Autophagy; Benzoates; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; Diketopiperazines; G2 Phase; Humans; Lung Neoplasms; Mitosis; Piperazines; Signal Transduction | 2013 |
Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Drug Evaluation; Humans; Lung Neoplasms; Melanoma; Piperazines; Skin Neoplasms; Thrombocytopenia | 1979 |